Orchestra BioMed Gets FDA Nod for BackBeat Study
By Dean Seal
Orchestra BioMed has gotten the go-ahead from federal regulators to start a study examining BackBeat, its atrioventricular interval modulation therapy for treating hypertension in pacemaker patients.
The biomedical company said Tuesday that the U.S. Food and Drug Administration has granted approval of an investigational device exemption that will allow the study to move forward.
Orchestra BioMed partnered with Medtronic on development and commercialization of the therapy in July 2022.
The company plans to begin enrollment in the BackBeat study before the end of this year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 19, 2023 08:09 ET (12:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst